Skip to content
S504Senate2023-2024 SessionSame asA4141

End Insulin Out-of-Pocket Costs

Official title

“Prohibits cost sharing for insulin”

Sponsor Gustavo RiveraSD-33+8 co-sponsorsAffects Finance
Status
In Assembly Committee
Insurance
Impact
8/10
Significant
Passage
0%

Bill progress

Step 5 of 7

In Assembly · Insurance

What's happening

This bill prohibits insurance companies from charging any out-of-pocket costs for prescription insulin in New York.

Why it matters

  1. Eliminates all out-of-pocket costs. for insulin, ensuring that people who rely on this life-saving medication will not face any deductibles, copays, coinsurance, or other cost-sharing requirements, regardless of their insurance plan.

  2. Goes beyond previous cost caps. by removing the existing $100-per-30-days limit and replacing it with a complete prohibition on any direct charges to patients for prescription insulin.

  3. May lead to increased medication adherence and better health outcomes. for individuals with diabetes, since financial barriers are a common reason patients skip or ration insulin doses.

  4. Could impact insurance premiums or plan structures. as insurers will be required to fully cover the costs of insulin prescriptions, which may have broader implications for how insurance risk and costs are distributed.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Insured patients who use insulin

    The bill would eliminate deductibles, copayments, coinsurance and other cost sharing for covered prescription insulin, replacing the $100 cap per 30-day supply.

  • Health insurers

    Insurers subject to the amended provisions would need to remove insulin cost sharing from policies or contracts issued, renewed, modified, altered or amended on or after January 1, 2025.

  • Diabetes patient advocates

    The bill would address patients’ out-of-pocket costs for covered prescription insulin by prohibiting cost sharing rather than capping it.

Headline styles

End Insulin Out-of-Pocket Costs

Plain English, a few words. Used as the page title.

Sponsors

History

  1. Referred to insurance
  2. Delivered to assembly
  3. Passed senateVote 61–1
  4. Amended on third reading (t) 504a
  5. Advanced to third reading
  6. 2nd report cal.
  7. 1st report cal.91
  8. Referred to insurance
  9. Returned to senate
  10. Died in assembly
  11. Referred to insurance
  12. Delivered to assembly
Show 4 earlier actions
  1. Passed senateVote 60–2
  2. Ordered to third reading cal.73
  3. Reported and committed to rules
  4. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A4141Assembly

End Insulin Copays

In Assembly Committee · Insurance · Sponsor Phara Souffrant Forrest

Impact 8 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

504--A Cal. No. 91

2023-2024 Regular Sessions

IN SENATE

January 4, 2023

Introduced by Sens. RIVERA, ADDABBO, COONEY, LIU, MARTINEZ -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance -- recommitted to the Committee on Insurance in accordance with Senate Rule 6, sec. 8 -- reported favorably from said committee, ordered to first and second report, ordered to a third reading, amended and ordered reprinted, retaining its place in the order of third reading

AN ACT to amend the insurance law, in relation to prohibiting cost sharing for insulin

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subparagraph (B) of paragraph 15-a of subsection (i) of section 3216 of the insurance law, as amended by section 1 of part DDD of chapter 56 of the laws of 2020, is amended to read as follows:

(B) Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, [the total amount] that [a covered person is required to pay out of pocket for] covered prescription insulin drugs shall [be capped at an amount not to exceed one hundred dollars per thirty-day supply, regardless of the amount or type of insulin needed to fill such covered person's prescription and regardless of the insured's] not be subject to a deductible, copayment, coinsurance or any other cost sharing requirement.

§ 2. Subparagraph (B) of paragraph 7 of subsection (k) of section 3221 of the insurance law, as amended by section 2 of part DDD of chapter 56 of the laws of 2020, is amended to read as follows:

(B) Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, [the total amount] that [a covered person is required

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02649-04-4

to pay out of pocket for] covered prescription insulin drugs shall [be capped at an amount not to exceed one hundred dollars per thirty-day supply, regardless of the amount or type of insulin needed to fill such covered person's prescription and regardless of the insured's] not be subject to a deductible, copayment, coinsurance or any other cost sharing requirement.

§ 3. Paragraph 2 of subsection (u) of section 4303 of the insurance law, as amended by section 3 of part DDD of chapter 56 of the laws of 2020, is amended to read as follows:

(2) Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, [the total amount] that [a covered person is required to pay out of pocket for] covered prescription insulin drugs shall [be capped at an amount not to exceed one hundred dollars per thirty-day supply, regardless of the amount or type of insulin needed to fill such covered person's prescription and regardless of the insured's] not be subject to a deductible, copayment, coinsurance or any other cost sharing requirement.

§ 4. This act shall take effect January 1, 2025 and shall apply to any policy or contract issued, renewed, modified, altered, or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law, in relation to prohibiting cost shar- ing for insulin

Summary of provisions

Sections 1 through 3 of the bill amend various sections of insurance law which were amended as part DDD of Chapter 56 of the laws of 2020; the adopted budget, to eliminate any deductible, copayment, coinsurance or any other cost sharing requirement for insulin drugs.

Section 4 of the bill provides for an effective date.

Justification

An estimated 1.6 million New Yorkers have diabetes and many type 2 diabetics are insulin dependent. Each year there are thousands of hospi- talizations in NY with a principal diagnosis of diabetes-related compli- cations including diabetic ketoacidosis.

Type 1 and some Type 2 diabetics depend upon insulin for their very survival. In 2016, the average person with type 1 diabetes incurred annual insulin costs of $5,705.00. While some pay less, many others pay many times this amount. When patients can't afford insulin, which can cost thousands of dollars even for those who are insured, they resort to rationing the little medication they can afford. In fact, one study found that one in four people with type 1 diabetes admitted to not taking their insulin as prescribed or rationing due to the cost. Compli- cations from rationing insulin are extreme, leading to amputations, Diabetic Ketoacidosis, also referred to as DKA, and even death.

As part of the adopted SFY 2020-21 state budget, a cap of $100 on cost sharing was adopted (Part DDD, Chapter 56 of 2020). However, the budget language capped cost sharing per prescription. Given many diabetics rely on two or three different types of insulin, they may still have cost sharing of $300 per month. This legislation would eliminate any deduct- ible, copayment, coinsurance or any other cost sharing requirement for insulin drugs.

Prior legislative history

2023 - S504 (Rivera) - Passed Senate

2022 - S1413 (Rivera) - Passed Senate

2021 - S1413 (Rivera) - Passed Senate

2020 - S8255 (Rivera) - Passed Senate

Fiscal implications

No cost to the state.

Effective date

Immediately and shall apply to any policy or contract written or renewed on or after January 1, 2023.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.